Prostate Cancer

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.

177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Capivasertib plus docetaxel continued to show an improvement in overall survival compared with docetaxel alone in patients with metastatic castration-resistant prostate cancer.

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

The American Urologic Association in collaboration with the American Society for Radiation Oncology has issued new practice guidelines for the management of clinically localized prostate cancer.

The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).

The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.

The combination of darolutamide plus androgen deprivation therapy and docetaxel presents adverse effects that are similar to those experienced with ADT plus docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.

Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.

Darolutamide elicited consistent benefits in overall survival and prostate-specific antigen outcomes, irrespective of prior local therapy with radiotherapy or radical prostatectomy, in patients with nonmetastatic castration-resistant prostate cancer.

Results from a detailed safety analysis of the pivotal phase 3 HERO trial showed that relugolix, an oral gonadotropin-releasing hormone receptor antagonist, had an acceptable toxicity profile with favorable tolerability in patients with advanced prostate cancer.

Enzalutamide added to androgen deprivation therapy demonstrated a benefit in overall survival, radiographic progression-free survival, undetectable prostate-specific antigen rates, objective response rates, and other end points vs placebo/ADT in patients with metastatic hormone-sensitive prostate cancer regardless of whether or not they received prior local therapy.

Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

The addition of niraparib to abiraterone acetate and prednisone achieved for promising response rates in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

PET/CT scans conducted with 18F-rhPSMA-7.3 frequently resulted in post-scan disease upstaging compared with baseline conventional imaging in patients with prostate cancer recurrence.

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.